PROVIDER BULLETIN PROVIDER INFORMATION



March 1, 2021

Updated Minnesota Health Care Programs and Minnesota Senior Health Options Prior Authorization and Medical Policy Requirements

Effective May 3, 2021, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) will be updating its government programs medical policy and pre-authorization/pre-certification/notification lists. The lists clarify medical policy, prior authorization and notification requirements for the Minnesota Health Care Programs (Families and Children, MinnesotaCare and Minnesota Senior Care Plus) and Minnesota Senior Health Options (MSHO) products.

As stewards of healthcare expenditures for our members, we are charged with ensuring they receive appropriate, quality care, while also maintaining overall costs. The prior authorization process ensures that the health service or drug being proposed is medically necessary, and reflective of evidence-based medicine and industry standards, prior to treatment. This process helps us manage the cost and quality of care appropriately for our members.

| Policy # | Policy Name | New Policy | Prior Authorization Required | |
|-------------|---|---------------|---------------------------------|------|
| | | | Medicaid | MSHO |
| CG-LAB-15 | Red Blood Cell Folic Acid Testing | Yes | No | No |
| CG-LAB-16 | Serum Amylase Testing | Yes | No | No |
| GENE.00055 | Gene Expression Profiling for Risk Stratification of Inflammatory Bowel Disease (IBD) Severity | Yes | No | No |
| LAB.00037 | Serologic Testing for Biomarkers of Irritable Bowel Syndrome (IBS) | Yes | No | No |
| SURG.00158 | Implantable Peripheral Nerve Stimulation Devices as a Treatment for Pain | Yes | No | No |
| ING-CC-0181 | Veklury (remdesivir) | Yes | No | No |
| ING-CC-0185 | Oxlumo (lumasiran) | Yes | Yes | Yes |
| ING-CC-0184 | Danyelza (naxitamab-gqgk) | Yes | Yes | Yes |
| ING-CC-0177 | Zilretta (triamcinolone acetonide extended-release) | Yes | Yes | Yes |

The following *new* policies and/or prior authorization requirements will be applicable to member claims on or after May 3, 2021.

Distribution: bluecrossmn.com/providers/forms-and-publications Bulletin P13-21

Blue Cross® and Blue Shield® of Minnesota and Blue Plus® are nonprofit independent licensees of the Blue Cross and Blue Shield Association. Page 1 of 4

The following policies have changes in clinical criteria and **will be applicable** to member claims on or after **May 3, 2021**.

| Policy # | Policy Name | Prior Authorization Required | |
|-------------|---|---------------------------------|------|
| | | | MSHO |
| ADMIN.00001 | Medical Policy Formation | No | No |
| ANC.00009 | Cosmetic and Reconstructive Services of the Trunk and Groin | Yes | Yes |
| CG-GENE-18 | Genetic Testing for TP53 Mutations | Yes | Yes |
| CG-GENE-20 | Epidermal Growth Factor Receptor (EGFR) Testing | No | No |
| CG-LAB-14 | Respiratory Viral Panel Testing in the Outpatient Setting | No | No |
| CG-MED-38 | Inpatient Admission for Radiation Therapy for Cervical or Thyroid Cancer | No | No |
| CG-MED-53 | Cervical Cancer Screening Using Cytology and Human Papillomavirus Testing | No | No |
| CG-MED-59 | Upper Gastrointestinal Endoscopy in Adults | Yes | Yes |
| CG-MED-87 | Single Photon Emission Computed Tomography Scans for Noncardiovascular Indications | Yes | Yes |
| CG-SURG-94 | Keratoprosthesis | Yes | Yes |
| DME.00011 | Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices | No | No |
| GENE.00052 | Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling | Yes | Yes |
| MED.00116 | Near-Infrared Spectroscopy Brain Screening for Hematoma Detection | No | No |
| SURG.00011 | Allogeneic, Xenographic, Synthetic and Composite Products for Wound Healing and Soft Tissue Grafting | Yes | Yes |
| SURG.00062 | Vein Embolization as a Treatment for Pelvic Congestion Syndrome and Varicocele | No | No |
| SURG.00145 | Mechanical Circulatory Assist Devices (Ventricular Assist Devices, Percutaneous Ventricular Assist Devices and Artificial Hearts) | Yes | Yes |
| ING-CC-0059 | Selected Injectable NK-1 Antiemetic Agents | Yes | Yes |
| ING-CC-0056 | Selected Injectable 5HT3 Antiemetic Agents | Yes | Yes |
| ING-CC-0148 | Agents for Hemophilia B | Yes | Yes |
| ING-CC-0149 | Select Clotting Agents for Bleeding Disorders | Yes | Yes |
| ING-CC-0065 | Agents for Hemophilia A and von Willebrand Disease | Yes | Yes |
| ING-CC-0150 | Kymriah (tisagenlecleucel) | Yes | Yes |

| Policy # | Policy Name | Prior Authorization Required | |
|-------------|--|---------------------------------|------|
| - | | Medicaid | MSHO |
| ING-CC-0151 | Yescarta (axicabtagene ciloleucel) | Yes | Yes |
| ING-CC-0001 | Erythropoiesis Stimulating Agents | Yes | Yes |
| ING-CC-0121 | Gazyva (obinutuzumab) | Yes | Yes |
| ING-CC-0002 | Colony Stimulating Factor Agents | Yes | Yes |
| ING-CC-0003 | Immunoglobulins | Yes | Yes |
| ING-CC-0039 | GamaSTAN immune globulin (human) | Yes | Yes |
| ING-CC-0073 | Alpha-1 Proteinase Inhibitor Therapy | Yes | Yes |
| ING-CC-0075 | Rituximab Agents for Non-Oncologic Indications | Yes | Yes |
| ING-CC-0019 | Zoledronic Acid Agents (Reclast, Zometa) | Yes | Yes |
| ING-CC-0058 | Ocreotide Agents | Yes | Yes |

MCG Care Guidelines 24th Edition

Effective May 3, 2021, the following MCG Care Guideline 24th edition customizations will be implemented:

- Gastrointestinal Bleeding, Upper Gastrointestinal Bleeding (W0170) Revised the criteria for Clinical Indications for Admission to Inpatient Care and added reference and footnote.
- Gastrointestinal Bleeding, Upper: Observation Care (W0171) Revised Observation Care Admission Criteria

To view the summary of the MCG Care Guidelines 24th Edition customizations, select this <u>link</u>. Customizations to MCG Care Guidelines 24th Edition (publish date May 3, 2021).

For questions, please contact the Provider Services number on the back of the member's ID card.

Where do I find the current government programs Pre-Certification/Pre-Authorization/Notification list?

Go to https://provider.publicprograms.bluecrossmn.com/minnesota-provider/resources/prior-authorization

OR

Go to providers.bluecrossmn.com

Under Tools & Resources, select Minnesota Health Care Programs site

• Under Resources, select **Prior Authorization Requirements** and scroll down to *Related Information* to select **Prior Authorization Grid**

Where do I find the current government programs Medical Policy Grid?

Go to https://provider.publicprograms.bluecrossmn.com/minnesota-provider/resources/providermanuals-and-guides

Click on Medical Policies and UM Guidelines

OR

Go to providers.bluecrossmn.com

- Under Tools & Resources, select Minnesota Health Care Programs site
- Under Resources, select Manuals and Guides
- Click on Medical Policies and UM Guidelines

Where can I access medical policies?

• MN DHS (MHCP) Policies:

http://www.dhs.state.mn.us/main/idcplg?IdcService=GET_DYNAMIC_CONVERSION&RevisionSelec tionMethod=LatestReleased&dDocName=dhs16_157386

• Blue Cross Policies:

https://www.bluecrossmn.com/providers/medical-policy-and-utilization-management

• Amerigroup Policies:

https://provider.publicprograms.bluecrossmn.com/minnesota-provider/medical-policies-and-clinical-guidelines

and

https://www.anthem.com/pharmacyinformation/clinicalcriteria

Please note that the Precertification Look-Up Tool (PLUTO) is not available for prior authorization look up.

Questions?

If you have questions, please contact Blue Cross Provider Services at 1-866-518-8448.